Marco Castellana1, Carlo Castellana2, Luca Giovanella3, Pierpaolo Trimboli4,5. 1. National Institute of Gastroenterology "S. De Bellis", Castellana Grotte, Bari, Italy. 2. Margherita di Savoia 93, Putignano, 70017, Bari, Italy. 3. Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. 4. Clinic for Nuclear Medicine and Competence Center for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. pierpaolo.trimboli@gmail.com. 5. Scienze Biomediche, Università della Svizzera Italiana (USI), Lugano, Switzerland. pierpaolo.trimboli@gmail.com.
Abstract
PURPOSE: In patients with hypothyroidism, levothyroxine (LT4) is the treatment of choice, and tablets are the most commonly prescribed formulation. Despite multiple scenarios being reported in the literature with impaired tablet absorption and likely missed TSH targets, it is yet unclear what the implications are for clinical practice and the role of liquid solution (LS) and soft gel (SG) formulations. We have thus conducted a narrative review evaluating the prevalence within the general population of gastrointestinal disorders impacting tablet LT4 absorption. METHODS: PubMed and Google Scholar were searched until December 2019 for systematic reviews and meta-analyses on the topic. If they could not be retrieved, other types of manuscripts were searched. RESULTS: Lactose malabsorption and Helicobacter pylori infection represented the most common disorders, with a global prevalence of 68% and 48%, respectively. The prevalence of other conditions, including autoimmune gastritis, bariatric surgery, celiac disease, gastroparesis, giardiasis, liver cirrhosis, or ulcerative colitis, was lower than 20%. Data at regional and country levels were found to be heterogeneous, but at least one in five patients was diagnosed with one disorder. CONCLUSIONS: The worldwide prevalence of gastrointestinal disorders associated with tablet LT4 malabsorption, including lactose malabsorption and Helicobacter pylori infection, is high. Interactions with drugs or food can further increase this risk. Considering that all studies investigating the impact of switching patients from tablet to LS or SG found an improved thyroid balance, the latter formulations should be considered as first-line therapy for managing hypothyroidism.
PURPOSE: In patients with hypothyroidism, levothyroxine (LT4) is the treatment of choice, and tablets are the most commonly prescribed formulation. Despite multiple scenarios being reported in the literature with impaired tablet absorption and likely missed TSH targets, it is yet unclear what the implications are for clinical practice and the role of liquid solution (LS) and soft gel (SG) formulations. We have thus conducted a narrative review evaluating the prevalence within the general population of gastrointestinal disorders impacting tablet LT4 absorption. METHODS: PubMed and Google Scholar were searched until December 2019 for systematic reviews and meta-analyses on the topic. If they could not be retrieved, other types of manuscripts were searched. RESULTS:Lactose malabsorption and Helicobacter pylori infection represented the most common disorders, with a global prevalence of 68% and 48%, respectively. The prevalence of other conditions, including autoimmune gastritis, bariatric surgery, celiac disease, gastroparesis, giardiasis, liver cirrhosis, or ulcerative colitis, was lower than 20%. Data at regional and country levels were found to be heterogeneous, but at least one in five patients was diagnosed with one disorder. CONCLUSIONS: The worldwide prevalence of gastrointestinal disorders associated with tablet LT4 malabsorption, including lactose malabsorption and Helicobacter pylori infection, is high. Interactions with drugs or food can further increase this risk. Considering that all studies investigating the impact of switching patients from tablet to LS or SG found an improved thyroid balance, the latter formulations should be considered as first-line therapy for managing hypothyroidism.
Entities:
Keywords:
Hypothyroidism; Levothyroxine; Liquid; Malabsorption; Review; Soft gel
Authors: Erik K Alexander; Elizabeth N Pearce; Gregory A Brent; Rosalind S Brown; Herbert Chen; Chrysoula Dosiou; William A Grobman; Peter Laurberg; John H Lazarus; Susan J Mandel; Robin P Peeters; Scott Sullivan Journal: Thyroid Date: 2017-03 Impact factor: 6.568
Authors: Nayahmka J McGriff; Gyorgy Csako; Loukas Gourgiotis; Guthrie Lori C; Frank Pucino; Nicholas J Sarlis Journal: Ann Med Date: 2002 Impact factor: 4.709
Authors: Renato Bandeira de Mello; Karina Giassi; Gabriela Stahl; Maria Luisa Machado Assis; Marina Siqueira Flores; Bruna Cambrussi de Lima; Vanessa Piccoli; Ticiana da Costa Rodrigues Journal: Front Med (Lausanne) Date: 2022-06-23
Authors: Jurjen S Kingma; Desirée M T Burgers; Valerie M Monpellier; Marinus J Wiezer; Heleen J Blussé van Oud-Alblas; Janelle D Vaughns; Catherine M T Sherwin; Catherijne A J Knibbe Journal: Br J Clin Pharmacol Date: 2021-06-03 Impact factor: 3.716